We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.
- Authors
Volpe, Massimo; Galiuto, Leonarda
- Abstract
The FINEARTS-HF trial evaluated the efficacy and safety of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in patients with heart failure and mildly reduced or preserved ejection fraction. The trial showed that finerenone significantly reduced total worsening heart failure events and cardiovascular death compared to a placebo. While finerenone improved patient-reported symptom scores, it did not show a significant difference in kidney outcomes or New York Heart Association functional class improvement. The study highlighted the potential benefits of finerenone in managing heart failure, particularly in reducing worsening heart failure events.
- Subjects
DISEASE risk factors; HEART failure patients; ANGIOTENSIN-receptor blockers; ACE inhibitors; SYSTOLIC blood pressure
- Publication
European Heart Journal, 2025, Vol 46, Issue 1, p103
- ISSN
0195-668X
- Publication type
Academic Journal
- DOI
10.1093/eurheartj/ehae679